High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function

Transplant Immunology

Volumn 20, Issue 4, 2009, Pages 238-242

  Nickel, Peter ^a   Bold, Gantuja ^a   Presber, Franziska ^a   Biti, Didier ^a   Babel, Nina ^a   Kreutzer, Stephanie ^a   Pratschke, Johann ^a   Schönemann, Constanze ^a   Kern, Florian ^a   Volk, Hans Dieter ^a   Reinke, Petra ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cytomegalovirus; ELISPOT; Immune monitoring; Kidney transplantation; T cells

Indexed keywords

CELL ADHESION MOLECULE; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; IMMEDIATE EARLY PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ACUTE GRAFT REJECTION; ADULT; ALLOIMMUNITY; ANTIBODY SPECIFICITY; ARTICLE; CADAVER KIDNEY; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART GRAFT; HUMAN; IMMUNOREACTIVITY; IMMUNOSTIMULATION; INTERFERON PRODUCTION; KIDNEY DONOR; KIDNEY GRAFT; LIVING DONOR; LUNG TRANSPLANTATION; MALE; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ADULT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PEPTIDES; PHOSPHOPROTEINS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; VIRAL MATRIX PROTEINS;

EID: 59649125190     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2008.11.002     Document Type: Article

References (29)

1. Fishman J.A., and Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 338 24 (Jun 11 1998) 1741-1751
2. Cainelli F., and Vento S. Infections and solid organ transplant rejection: a cause-and-effect relationship?. Lancet Infect Dis 2 9 (Sep 2002) 539-549
3. Lautenschlager I., Soots A., Krogerus L., Kauppinen H., Saarinen O., Bruggeman C., et al. Effect of cytomegalovirus on an experimental model of chronic renal allograft rejection under triple-drug treatment in the rat. Transplantation 64 3 (Aug 15 1999) 391-398
4. Streblow D.N., Kreklywich C., Yin Q., De La Melena V.T., Corless C.L., Smith P.A., et al. Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants. J Virol 77 3 (Feb 2003) 2182-2194
5. Opelz G., Dohler B., and Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transpl 4 6 (Jun 2004) 928-936
6. Reinke P., Fietze E., Ode-Hakim S., Prosch S., Lippert J., Ewert R., et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 344 8939-8940 (Dec 24-31 1994) 1737-1738
7. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202 5 (Sep 5 2005) 673-685
8. Reinke P., Prosch S., Kern F., and Volk H.D. Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transpl Infect Dis 1 3 (Sep 1999) 157-164 [Review]
9. Selin L.K., and Brehm A. Frontiers in nephrology: heterologous immunity, T cell cross-reactivity, and alloreactivity. J Am Soc Nephrol 18 (2007) 2268-2277
10. Adams A.B., Williams M.A., Jones T.R., Shirasugi N., Durham M.M., Kaech S.M., et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 111 12 (Jun 2003) 1887-1895
11. Selin L.K., Brehm M.A., Naumov Y.N., Cornberg M., Kim S.K., Clute S.C., et al. Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. Immunol Rev 211 (2006) 164-181
12. Cinatl J., Vogel J.U., Kotchetkov R., Scholz M., and Doerr H.W. Proinflammatory potential of cytomegalovirus infection. Intervirology 42 (1999) 419-424
13. Grundy J. Current antiviral therapy fails to prevent the proinflammatory effects of cytomegalovirus infection, whilst rendering infected cells relatively resistant to immune attack. In: Scholz M.R.H., Rabena H.F., Doerr H.W., and Cinatl Jr. J. (Eds). CMV-related immunopathology (1998), Karger, Basel 67-89
14. Streblow D.N., Orloff S.L., and Nelson J.A. Acceleration of allograft failure by cytomegalovirus. Curr Opin Immunol 19 5 (Oct 2007) 577-582
15. Kern F., Surel I.P., Brock C., Freistedt B., Radtke H., Scheffold A., et al. T cell epitope mapping by flow cytometry. Nat Med 4 8 (Aug 1998) 975-978
16. Bunde T., Kirchner A., Hoffmeister B., Habedank D., Hetzer R., Cherepnev G., et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201 7 (Apr 4 2005) 1031-1036
17. Nickel P., Presber F., Bold G., Biti D., Schönemann C., Tullius S.G., et al. Enzyme linked immunosorbent spot (ELISPOT) assay for donor-reactive interferon-gamma-producing cells identifies T cell presensitization and correlates with graft function at 6 and 12 months in renal transplant recipients. Transplantation 78 (2004) 1640-1646
18. Hricik D.E., Rodriguez V., Riley J., Bryan K., Tary-Lehmann M., Greenspan N., et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transpl 3 7 (Jul 2003) 878-884
19. Asadullah K., Prosch S., Audring H., Buttnerova I., Volk H.D., Sterry W., et al. A high prevalence of cytomegalovirus antigenaemia in patients with moderate to severe chronic plaque psoriasis: an association with systemic tumour necrosis factor alpha overexpression. Br J Dermatol 141 1 (Jul 1999) 94-102
20. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461
21. Hariharan S., McBride M.A., Cherikh W.S., Tolleris C.B., Bresnahan B.A., and Johnson C.P. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 62 (2002) 311
22. Iwamoto G.K., and Konicek S.A. Cytomegalovirus immediate early genes upregulate interleukin-6 gene expression. J Investig Med 45 4 (Apr 1997) 175-182
23. Crump J.W., Geist L.J., Auron P.E., Webb A.C., Stinski M.F., and Hunninghake G.W. The immediate early genes of human cytomegalovirus require only proximal promoter elements to upregulate expression of interleukin-1 beta. Am J Respir Cell Mol Biol 6 6 (Jun 1992) 674-677
24. Gratama J.W., Brooimans R.A., van der Holt B., Sintnicolaas K., van Doornum G., Niesters H.G., et al. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry Part B (Clinical Cytometry) 74B (2008) 211-22019
25. La Rosa C., Limaye A.P., Krishnan A., Longmate J., and Diamond D.J. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 195 5 (2007) 633-644
26. Lacey S.F., La Rosa C., Zhou W., Sharma M.C., Martinez J., Krishnan A., et al. Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J Infect Dis 194 (2006) 1410-1421
27. Lilleri D., Zelini P., Fornara C., Comolli G., and Gerna G. Inconsistent responses of cytomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant recipients. Am J Transpl 7 (2007) 1997-2005
28. Egli A., Binet I., Binggeli A., Jäger C., Dumoulin A., Schaub A., et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 6 (2008) 29
29. Einsele H., Kapp M., and Grigoleit G.U. CMV-specific T cell therapy. Blood Cells Mol Diseases 40 1 (Jan-Feb 2008) 71-75